Gastric and gastro-oesophageal cancer therapy

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 16, 2005, Pages 2805-2812

  Das, Prajnan ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Chemotherapy; Gastric cancer; Gastro oesophageal cancer; Neoadjuvant therapy; Radiotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; UVOMORULIN;

ALOPECIA; ANEMIA; ANOREXIA; BARRETT ESOPHAGUS; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG SAFETY; ENVIRONMENTAL FACTOR; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FATIGUE; FOOD INTAKE; GASTRECTOMY; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC POLYMORPHISM; GEOGRAPHIC DISTRIBUTION; HELICOBACTER INFECTION; HUMAN; INCIDENCE; INFECTION; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPHADENECTOMY; METAPLASIA; METASTASIS POTENTIAL; MORBIDITY; MORTALITY; NEUTROPENIA; OBESITY; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PROGNOSIS; QUALITY OF LIFE; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STOMACH CANCER; STOMATITIS; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; STOMACH NEOPLASMS;

EID: 29444451102     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.16.2805     Document Type: Review

References (57)

1. PARKIN DM, BRAY F, FERLAY J, PISANI P: Global cancer statistics, 2002. CA Cancer J. Clin. (2005) 55(2):74-108.
2. KARPEH MS, KELSEN DP, TEPPER JE: Cancer of the stomach. In: Cancer: Principles & Practice of Oncology. VT DeVita et al. (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2001):1092-1126.
3. DEVESA SS, BLOT WJ, FRAUMENI JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (1998) 83(10):2049-2053.
4. POSNER MC, FORASTIERE AA, MINSKY BD: Cancer of the esophagus. In: Cancer: Principles & Practice of Oncology. VT DeVita et al. (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2005):861-909.
5. CAMERON AJ, OTT BJ, PAYNE WS: The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N. Engl. J. Med. (1985) 313(14):857-859.
6. CSENDES A, SMOK G, BURDILES P et al.: Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis. Esophagus (2000) 13(1):5-11.
7. HAMPEL H, ABRAHAM NS, EL-SERAG HB: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann. Intern. Med. (2005) 143(3):199-211.
8. GUILFORD PJ, HOPKINS JB, GRADY WM et al.: E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum. Mutat. (1999) 14(3):249-255.
9. ZHANG J, LI Y, WANG R et al.: Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int. J. Cancer (2003) 105(2):281-284.
10. ZHENG L, WANG L, AJANI J, XIE K: Molecular basis of gastric cancer development and progression. Gastric Cancer (2004) 7(2):61-77.
11. STADTLANDER CT, WATERBOR JW: Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis (1999) 20(12):2195-2208.
12. SHIBATA A, PARSONNET J, LONGACRE TA et al.: CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis (2002) 23(3):419-424.
13. AMERICAN JOINT COMMITTEE ON CANCER: AJCC Cancer Staging Handbook, Sixth Edition. FL Greene et al. (Eds), Springer Verlag, New York, NY, USA (2002):111-118.
14. JAPANESE GASTRIC CANCER A: Japanese classification of gastric carcinoma - 2nd English Edition. Gastric Cancer (1998) 1(1):10-24.
15. KATTAN MW, KARPEH MS, MAZUMDAR M, BRENNAN MF: Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J. Clin. Oncol. (2003) 21(19):3647-3650.
16. PEETERS KC, KATTAN MW, HARTGRINK HH et al.: Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer (2005) 103(4):702-707.
17. HASEGAWA S, FURUKAWA Y, LI M et al.: Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res. (2002) 62(23):7012-7017.
18. INOUE H, MATSUYAMA A, MIMORI K, UEO H, MORI M: Prognostic score of gastric cancer determined by cDNA microarray. Clin. Cancer Res. (2002) 8(11):3475-3479.
19. WEISS MM, KUIPERS EJ, POSTMA C et al.: Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene (2003) 22(12):1872-1879.
20. MARUYAMA K, GUNVEN P, OKABAYASHI K, SASAKO M, KINOSHITA T: Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann. Surg. (1989) 210(5):596-602.
21. BONENKAMP JJ, HERMANS J, SASAKO M, VAN DE VELDE CJ: Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N. Engl. J. Med. (1999) 340(12):908-914.
22. CUSCHIERI A, WEEDEN S, FIELDING J et al.: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br. J. Cancer (1999) 79(9-10):1522-1530.
23. SANO T, SASAKO M, YAMAMOTO S et al.: Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J. Clin. Oncol. (2004) 22(14):2767-2773.
24. BIRKMEYER NJ, GOODNEY PP, STUKEL TA, HILLNER BE, BIRKMEYER JD: Do cancer centers designated by the National Cancer Institute have better surgical outcomes? Cancer (2005) 103(3):435-441.
25. MACDONALD JS, SMALLEY SR, BENEDETTI J et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. (2001) 345(10):725-730.
26. MEYERHARDT JA, FUCHS CS: Adjuvant therapy in gastric cancer: can we prevent recurrences? Oncology (2003) 17(5):714-721, 728.
27. AJANI JA, MANSFIELD PF, JANJAN N et al.: Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J. Clin. Oncol. (2004) 22(14):2774-2780.
28. AJANI JA, MANSFIELD PF, CRANE CH et al.: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J. Clin. Oncol. (2005) 23(6):1237-1244.
29. WILKE H, PREUSSER P, FINK U et al.: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a Phase II study with etoposide, doxorubicin, and cisplatin. J. Clin. Oncol. (1989) 7(9):1318-1326.
30. AJANI JA, MAYER RJ, OTA DM et al.: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J. Natl. Cancer Inst. (1993) 85(22):1839-1844.
31. CROOKES P, LEICHMAN CG, LEICHMAN L et al.: Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer (1997) 79(9):1767-1775.
32. KELSEN D, KARPEH M, SCHWARTZ G et al.: Neoadjuvant therapy of high-risk gastric cancer: a Phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J. Clin. Oncol. (1996) 14(6):1818-1828.
33. AJANI JA, MANSFIELD PF, LYNCH PM et al.: Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J. Clin. Oncol. (1999) 17(8):2403-2411.
34. DICKSON JL, CUNNINGHAM D: Systemic treatment of gastric cancer. Eur. J. Gastroenterol. Hepatol. (2004) 16(3):255-263.
35. CUNNINGHAM D, ALLUM WH, STENNING SP, WEEDEN S: Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J. Clin. Oncol. (2005) 23(16s):308s.
36. GLIMELIUS B, EKSTROM K, HOFFMAN K et al.: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. (1997) 8(2):163-168.
37. PYRHÔNEN S, KUITUNEN T, NYANDOTO P, KOURI M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer (1995) 71(3):587-591.
38. DI COSIMO S, FERRETTI G, FAZIO N et al.: Docetaxel in advanced gastric cancer-review of the main clinical trials. Acta Oncol. (2003) 42(7):693-700.
39. ROTH AD, MAIBACH R, MARTINELLI G et al.: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann. Oncol. (2000) 11(3):301-306.
40. ROTH AD, MAIBACH R, FAZIO N et al.: 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a Phase I-II trial. Ann. Oncol. (2004) 15(5):759-764.
41. MOISEYENKO V, AJANI J, TJULANDIN SA et al.: Final results of a randomized controlled Phase III trial (TAX 325) comparing docetaxel (T) comnbined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J. Clin. Oncol. (2005) 23(16S):308S.
42. KOHNE CH, CATANE R, KLEIN B et al.: Irinotecan is active in chemonaive patients with metastatic gastric cancer: a Phase II multicentric trial. Br. J. Cancer (2003) 89(6):997-1001.
43. AJANI JA, BAKER J, PISTERS PW et al.: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a Phase II study. Cancer (2002) 94(3):641-646.
44. AJANI JA, BAKER J, PISTERS PW et al.: Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (2002) 16(5 Suppl. 5):16-18.
45. POZZO C, BARONE C, SZANTO J et al.: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol. (2004) 15(12):1773-1781.
46. DANK M, ZALUSKI J, BARONE C et al.: Randomized Phase III trial of irinotecan (CPT-11) + 5FU/folinic add (FA) versus CDDP + 5FU in 1st-fine advanced gastric cancer patients. J. Clin. Oncol. (2005) 23(16S):308S.
47. LOUVET C, ANDRE T, TIGAUD JM et al.: Phase II study of oxaliplatin, fluorouracil, and folinic add in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. (2002) 20(23):4543-4548.
48. AL-BATRAN SE, ATMACA A, HEGEWISCH-BECKER S et al.: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J. Clin. Oncol. (2004) 22(4):658-663.
49. WATERS JS, NORMAN A, CUNNINGHAM D et al.: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br. J. Cancer (1999) 80(1-2):269-272.
50. SUMPTER & HARPER-WYNNE C, CUNNINGHAM, D et al.: Report of two protocol planned interim analyses in a randomised multicentre Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br. J. Cancer (2005) 92(11):1976-1983.
51. KOIZUMI W, KURIHARA M, NAKANO S, HASEGAWA K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology (2000) 58(3):191-197.
52. SAKATA Y, OHTSU A, HORIKOSHI N et al.: Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J. Cancer (1998) 34(11):1715-1720.
53. KOIZUMI W, TANABE S, SAIGENJI K et al.: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br. J. Cancer (2003) 89(12):2207-2212.
54. YOSHIDA R, NAKAJIMA M, NISHIMURA K et al.: Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther. (2003) 74(1):69-76.
55. CHOLLET P, SCHOFFSKI P, WEIGANG-KOHLER K et al.: Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur. J. Cancer (2003) 39(9):1264-1270.
56. AJANI JA, FAUST J, IKEDA K et al.: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J. Clin. Oncol. (2005) 23(28):6957-6965.
57. AJANI JA, PHAN A, YAO JC et al.: Multicenter Phase II study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC). J. Clin. Oncol. (2005) 23(16S):313S.